OPIS argues evidence for the therapeutic potential of psilocybin in addressing this debilitating condition warrants immediate reform to allow for legal access and further research.
Madden et al. shed light on the discursive, material and procedural barriers hindering the meaningful engagement of people who use drugs in UN drug-policy, while identifying strategies for resistance and change.
HRI provide a thorough analysis of global harm reduction provision, highlighting innovations and barriers as well as the need for substantial investment.
The Canadian Drug Policy Coalition provides an overview of drug-related challenges in Canada and pathways toward sustainable solutions anchored in public health and harm reduction.
AFEW's survey sheds light on the impact of the COVID-19 pandemic and associated restrictions on civil society in terms of their staff's health, operations and sustainability.
Steve Rolles et al. argue the regulation of illicit substances provides an effective avenue to manage the risks of drugs and drug markets, both for those who use them and for wider society.
INPUD reveals how the HIV epidemic in Kyrgyzstan is dangerously outpacing the country's response in terms of government aid and community-led initiatives to combat the crisis.
Shirley-Beavan et al. analyse the role of stigma and structural violence, gender-based violence, criminalisation and the absence of women-specific services.
Clean Start provides formerly-incarcerated women with avenues for healing, education and employment, breaking cycles of criminalisation and vulnerability.
The legalisation of the drug market as a way to undermine the power of organised crime groups and reducing the risk of vulnerable people by diminishing the opportunity and profit motive for human exploitation.
